string(10) "newsevents"

For the month of July, in the series of monthly business talks titled AI Industry Connect Talks we hosted Intelligencia. Invited speakers, Mr Dimitris Skaltsas, Co-founder, Mr Gerry Liaropoulos Director of Data Science and Mrs Violetta Kalathaki, Chief Product Officer at Intelligencia, delivered the talk: Drug development and the computational power of AI.

Watch the video of the talk here:


The talk took place on line via zoom.

Dimitris Skaltsas is a co-founder at Intelligencia. He has spent the past 10+ years in healthcare leadership roles. Before Intelligencia, Dimitris led McKinsey’s New Ventures for big data and AI in life sciences. He currently serves as an Executive in Residence for Digital and AI at INSEAD, and is an angel investor and advisor to early stage tech ventures. Dimitris has an MBA from INSEAD and a law degree from UCL and the University of Athens.

Violetta Kalathaki is the Chief Product Officer at Intelligencia. Violetta has several years of experience at Google where amongst other things she built products like Adsense Native ads and created a high touch Marketing acquisition team for Adwords. In addition to Google, she brings valuable experience from McKinsey as well as the startup ecosystem. Violetta holds a Master’s degree in Economics and Management from the LSE and a BS in Electrical and Computer Engineering from NTUA.
Gerry Liaropoulos is the Director of Data Science and Bioinformatics and leads the development of Intelligencia’s Machine Learning algorithms. Prior to joining Intelligencia, he spent several years as a quant trader for various asset classes and has built quantitative trading models in commodities, ETFs and futures. Gerry serves as a Machine Learning instructor at Propulsion Academy in Zurich. Gerry holds an MSc in Financial Economics from the University of Oxford, a diploma in Electrical and Computer Engineering from NTUA and has completed Advanced Studies in Computer Science at ETH Zürich.

About the company: Intelligencia is a technology company that focuses on reducing the risk of drug development and enabling external innovation, with the ultimate goal of bringing novel therapies to patients faster. At Intelligencia, we combine expertly curated, proprietary data with the computational power of AI to quantify and improve clinical success and to enhance external innovation. Our business model provides flexibility for our customers – this may include an all access option to our intuitive platform, subscription to select modules, and/or periodic bespoke reports. Our platform includes two products: (a) Portfolio Optimiser: to assess PTRS (Probability of Technical & Regulatory Success) for novel therapies and (b) breakthrough Science: to identify high potential emerging innovation, trends, areas of research. Intelligencia’s InSight Datacube brings together, with state-of-the-art machine learning models and expertly curated ontologies, billions of proprietary and public data points across clinical and preclinical development that produce trusted results. Our customers, pharmaceutical companies and biotechs ranging from multi-billion large-cap to emerging preclinical, use Intelligencia’s platform to:

  • Assess the probability of technical and regulatory success (PTRS) of their development programs and minimise any risks
  • Optimise trial design and evaluate additional indications for a clinical asset
  • Evaluate the relative attractiveness of external assets
  • Predict likely future areas of scientific innovation


The AI Industry Connect Talks series was launched in March 2021 by SKEL | The Artificial Intelligence Lab, Institute of Informatics & Telecommunications at NCSR Demokritos and is supported by ahedd Digital Innovation Hub. Through this series of talks, we aim to bring AI innovation to the forefront and inform wider audiences of the endless possibilities. Domain professionals tell us how the Industry applies scientific results in real-life.

A Q&A session follows the presentations. The sessions are live-streamed via Zoom and on YouTube.

[See all previous talks in the dedicated webpage here – [Marine Traffic, Contexity, Causaly, Atypon, LifebitJADBioElsevierQualcoBehavioral SignalsSCiFY, PurposefulOmilia, Pollfish, Accenture]

Skip to content